Struggling genetic testing company 23andMe plans to cut 200 jobs, stop developing therapies, and incur $12m in one-off costs. The CEO aims to revive the business amid a 70% share price drop this year.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing